BRCA1 and breast carcinoma: In a Phase III TNT study, to compare the effectiveness of carboplatin and docetaxel in TNBC or germline BRCA1/2 mutation-positive breast cancer with metastatic recurrence, both overall response rate (ORR) and progression-free survival (PFS) were significantly improved in the carboplatin-treated group (ORR: 68% vs. 33.3%, median PFS: 6.8 months vs. 4.4 months).